Arrowhead Research Corp. (ARWR, Financial) filed Quarterly Report for the period ended 2011-12-31.
Arrowhead Research Corp. has a market cap of $54.4 million; its shares were traded at around $5.19 with and P/S ratio of 183.8.
Revenue associated with research and development funding payments under collaborative agreements is recognized ratably over the relevant periods specified in the agreement, generally the research and development period. Revenue from up-front license fees, milestones and product royalties are recognized as earned based on the completion of the milestones and product sales, as defined in the respective agreements. Payments received in advance of recognition as revenue are recorded as deferred revenue.
The Company recorded revenue of $23,958 during the three months ended December 31, 2011, as compared to $296,139 during the quarter ended December 31, 2010. The revenue in 2011 was related to two license agreements acquired in conjunction with the acquisition of Roche Madison, Inc. The revenue in 2010 was related to grants received in the quarter. Revenue for the quarter ended December 31, 2010 associated with Unidym prior to its disposition is presented as a part of discontinued operations.
Read the The complete Report
Arrowhead Research Corp. has a market cap of $54.4 million; its shares were traded at around $5.19 with and P/S ratio of 183.8.
Highlight of Business Operations:
Based upon the Companys cash on hand and operating plan at December 31, 2011, collections from financings during the three months ended December 31, 2011 and other sources of liquidity, as described above, the Companys management anticipates that the Company will be able to satisfy the cash requirements of its operations through at least the next twelve months. However, the Company anticipates that further equity financings, and/or asset sales and license agreements will be necessary to continue to fund operations in the future.Revenue associated with research and development funding payments under collaborative agreements is recognized ratably over the relevant periods specified in the agreement, generally the research and development period. Revenue from up-front license fees, milestones and product royalties are recognized as earned based on the completion of the milestones and product sales, as defined in the respective agreements. Payments received in advance of recognition as revenue are recorded as deferred revenue.
The Company recorded revenue of $23,958 during the three months ended December 31, 2011, as compared to $296,139 during the quarter ended December 31, 2010. The revenue in 2011 was related to two license agreements acquired in conjunction with the acquisition of Roche Madison, Inc. The revenue in 2010 was related to grants received in the quarter. Revenue for the quarter ended December 31, 2010 associated with Unidym prior to its disposition is presented as a part of discontinued operations.
Read the The complete Report
